October 22, 2025

Molecular

Reminder: The new NGS assays for the MPN-associated biomarkers (JAK2, CALR, and MPL) are now available.

• The NGS assays replace the old tests that were performed by PCR, bi-directional sequencing and/or fragment length analysis (FLA). See below table.
  • Orders of the old tests will be automatically accessioned for the new tests.
• Test names now reflect the change in methodology and accurately describe the scope of JAK2 testing. The updates are highlighted in bold in the table.
• CPT codes and pricing will remain the same.
• Paper requisitions have been updated and are available for orders with Client Services or download on NeoGenomics website.
• NYS Approval: The NGS versions are not NYSDOH-approved. NYS orders are processed with the old methodology until approval is received for the NGS assays.
• For Interface Clients: This test update will involve a change in test names and codes. Please refer to the Interface Updates section for more info.

Note: This methodology change does NOT apply to JAK2 V617F Mutation Analysis – Quantitative. The quantitative test remains the same.

c-MET CDx for NSCLC

NeoGenomics is proud to offer a c-MET CDx for NSCLC to support precision oncology in non-small cell lung cancer (NSCLC). This advanced immunohistochemistry (IHC) assay enables precise detection of MET protein expression, empowering oncologists to identify patients with NSCLC who may benefit from a new targeted therapy.

Learn how c-MET testing can transform your approach to lung cancer care. We invite you to visit us online.

Personalized patient care starts with precision oncology.

Claudin18 is a new actionable target for patients with advanced or metastatic gastric/GEJ adenocarcinoma who may be eligible for biomarker-driven therapy. NeoGenomics is one of the leading laboratories that offers Claudin18 testing. Biomarker-informed decision-making reveals opportunities to advance care and identify those who may benefit from targeted therapies.

Learn how Claudin18.2 testing can transform your approach to gastric cancer care. We invite you to visit us online.

Leverage Comprehensive Genomic Profiling (CGP) for MDS, CMML, and Other Myeloid Neoplasms

CGP plays a pivotal role in differentiating disease subtypes and resolving complex diagnostic challenges associated with MDS and CMML with greater clarity and confidence than traditional diagnostic testing.¹

Neo Comprehensive – Myeloid Disorders®, a guideline-driven CGP assay, uses DNA and RNA NGS to detect relevant aberrations for diagnostic evaluation, prognosis, risk stratification, and therapy guidance for MDS, CMML, and other myeloid disorders, driving informed care. Learn more about this testing solution.

1. Puentes, R. The Importance of Comprehensive Testing in Myeloid Neoplasms: Insights from Real-World Genomics Data. NeoGenomics Laboratories; 2025. Accessed October 10, 2025.

IDHNow for AML Sponsored Testing Program

For AML patients, time is of the essence. Get IDHNow for AML for informed treatment decisions.

NeoGenomics has partnered with Servier to provide IDHNow for AML, a sponsored testing program for eligible AML patients. Participating patients benefit from expedited IDH1 profiling results, allowing you to make treatment decisions as quickly as possible for your patients. Patients with newly diagnosed AML who do not have a known IDH1 mutation, and who reside and receive treatment in the US and its territories may be eligible for the IDHNow for AML Sponsored Testing Program at no cost.

To learn more and order today, please visit our website.

For a complete list of recent test updates, click here for a downloadable document to view the impacted interface test codes.

Welcome to Oncology View - A New Resource for Oncology Professionals
NeoGenomics is launching an oncology-specific blog to help keep you at the forefront of innovation in cancer care. The goal is to provide busy oncology professionals and pharma business partners with concise, practical updates that support Oncology practices and therapy commercialization.

Every month, we will deliver proprietary blog content which will include a relevant topic, such as:

• Highlights from key scientific meetings (ASCO, ESMO, SABCS, etc.)
• Biomarker and testing updates to guide precision oncology decisions
• Clinical insights and case studies from NeoGenomics or thought leaders
• Product and service news to enhance your practice
• Tools and resources to simplify diagnostic and treatment planning

Thank you for your dedication to advancing cancer care. We look forward to sharing insights that help you make an even greater impact on the patients you serve.

Lisa Whitmyer,
VP Global Marketing

READ MORE HERE...